Vaccinex Initiates Nasdaq Delisting Amid Strategic Shift Vaccinex has started the process of delisting its stock from Nasdaq, citing plans to file a Form 25 with the SEC. The company aims to focus on developing its lead drug, pepinemab, targeting Alzheimer's and cancer, and to secure alternative funding through partnerships and grants.12